NG Bio invests in early-stage health tech and biotech companies, writing check sizes between $500,000 and $10 million. Their team, comprising scientists, drug developers, and entrepreneurs, collaborates with academic and scientific founders to develop therapies for autoimmune and chronic inflammatory diseases. Notable investments include Mesenbio. NG Bio is committed to bringing innovative technologies to patients in need.
